What is mesenchymal chondrosarcoma?
Mesenchymal chondrosarcoma is a rare, high-grade cancer that can start in bone or in soft tissue. It belongs to the chondrosarcoma family, the group of cancers that make cartilage. Unlike the common, slow-growing types of chondrosarcoma, it is fast-growing and tends to affect teenagers and young adults.
Under the microscope the tumour has two parts. Most of it is made of small, round, primitive cells that look a little like Ewing sarcoma. Scattered among them are islands of cartilage. This mixture of primitive cells and cartilage is the hallmark of the disease.
Nearly all of these tumours carry a specific gene fusion called HEY1::NCOA2. Finding this fusion confirms the diagnosis and separates the tumour from look-alikes (Baldi et al., 2026).
How it differs from conventional chondrosarcoma
Most chondrosarcomas are conventional chondrosarcomas, described on our page on chondrosarcoma. These usually affect older adults, grow slowly in the pelvis or long bones, and respond poorly to chemotherapy.
| Feature | Conventional chondrosarcoma | Mesenchymal chondrosarcoma |
|---|---|---|
| Share of chondrosarcomas | About three in four | Around 2% |
| Typical age | Middle-aged and older adults | Teenagers and young adults |
| Site | Bone only | Bone or soft tissue, including the head and neck |
| Cells | Cartilage throughout | Small round cells with cartilage islands |
| Gene change | Often IDH1 or IDH2 | HEY1::NCOA2 fusion |
| Chemotherapy | Little benefit | Often used |
Hameed (2021) lists mesenchymal chondrosarcoma as roughly 2% of all chondrosarcomas, while other authors give a range of 2-10% (Qi et al., 2022).
1. Key facts at a glance
| Feature | Details |
|---|---|
| Type of cancer | High-grade sarcoma with small round cells and cartilage |
| How common | Very rare |
| Typical age | Peak from the teenage years to the 30s |
| Common sites | Jaw and skull, spine, ribs, pelvis; soft tissue of the head, neck, brain coverings and limbs |
| Gene change | HEY1::NCOA2 fusion |
| Main treatment | Wide surgical removal |
| Other treatments | Chemotherapy and radiotherapy in many patients |
| Typical spread | Lungs and bone, sometimes many years after diagnosis |
| Outlook | Variable; late relapse is common, so long-term follow-up is needed |
2. Types
By site of origin
| Type | Typical locations | Notes |
|---|---|---|
| Skeletal (bone) | Jaw bones, skull, ribs, spine, pelvis | Often found as a painful swelling |
| Extraskeletal (soft tissue) | Coverings of the brain and spine, eye socket, thigh and other soft tissues | Can arise far from bone |
In a German study of young patients aged 25 or under, 11 of 15 tumours were outside bone and six were in the head and neck (Dantonello et al., 2008).
By microscopic appearance
| Pattern | Description |
|---|---|
| Classic biphasic | Primitive round cells with clear islands of cartilage |
| Cartilage-poor | Few cartilage islands; harder to diagnose on a small biopsy |
| Spindle cell areas | Some tumours contain elongated cells |
3. Causes and risk factors
The cause is not known. The disease arises from a gene change that happens by chance in a single cell.
| Factor | Notes |
|---|---|
| HEY1::NCOA2 fusion | Present in the tumour cells only; not inherited |
| Age | Mainly adolescents and young adults |
| Sex | Both sexes |
| Previous radiotherapy | No clear link |
| Inherited syndromes | None known |
| Lifestyle | No known link |
What does the fusion do?
Two genes, HEY1 and NCOA2, break and join together. The new combined gene makes a protein that switches on growth programmes normally used during early development. Laboratory work showed that the fusion protein boosts cell growth and raises the activity of the PDGF and AKT signalling pathways, which might become targets for future drugs (Qi et al., 2022).
4. How does it look
On scans
| Scan | Typical findings |
|---|---|
| X-ray | A destructive bone lesion, sometimes with speckled or ring-like calcification from cartilage |
| CT | Shows bone destruction and calcified spots |
| MRI | Defines the soft tissue mass and its relation to nerves, vessels and the brain |
| PET-CT | Helps with staging |
| Bone scan | May be used to look for spread to other bones |
Under the microscope
| Feature | Description |
|---|---|
| Small round cells | Sheets of primitive cells with little cytoplasm |
| Cartilage islands | Well-formed cartilage that may calcify |
| Branching vessels | Thin-walled, branching “staghorn” blood vessels |
| Stains | SOX9 and CD99 often positive; NKX2.2 may be positive |
| Molecular test | HEY1::NCOA2 fusion by sequencing or FISH |
The small round cells can make the tumour look like Ewing sarcoma, synovial sarcoma or a solitary fibrous tumour, especially on a small biopsy. Molecular testing helps to sort these out.
5. Symptoms
Symptoms depend on where the tumour grows.
Common symptoms
- Pain in a bone or the affected area
- A lump or swelling, often growing over weeks or months
- Stiffness or reduced movement of a nearby joint
Symptoms by site
| Site | Possible symptoms |
|---|---|
| Jaw | Swelling of the face, loose teeth, numbness of the lip or chin |
| Skull and brain coverings | Headaches, seizures, weakness, vision changes |
| Eye socket | Bulging of the eye, double vision |
| Spine | Back pain, numbness or weakness in the legs, bladder or bowel problems |
| Ribs or chest | Chest wall lump, pain on breathing |
| Limbs | Painful swelling, limp |
When to seek medical advice
See a doctor about any persistent bone pain, particularly at night, or a lump that is growing. Seek urgent help for sudden weakness, loss of bladder or bowel control, or a new seizure.
6. Diagnosis
| Step | What is done |
|---|---|
| History and examination | Assesses symptoms and the lump |
| X-ray and MRI | Images the primary tumour |
| Core needle biopsy | Planned by the sarcoma surgeon so the track can be removed later |
| Pathology review | Ideally at a specialist sarcoma laboratory |
| Molecular testing | Confirms HEY1::NCOA2 fusion |
| CT of the chest | Looks for lung spread |
| PET-CT or bone scan | Looks for spread elsewhere |
Staging
| Stage group | Simplified meaning |
|---|---|
| Localised | Tumour limited to its site of origin |
| Locally advanced | Large tumour or spread into nearby structures |
| Metastatic | Spread to lungs, bones or other organs |
All mesenchymal chondrosarcomas are treated as high-grade tumours.
7. Treatment
Treatment is planned by a bone and soft tissue sarcoma team. Because the disease is so rare, there are no randomised trials, and plans are based on case series.
Surgery
| Aspect | Details |
|---|---|
| Aim | Complete removal with a wide margin of healthy tissue |
| Limbs | Limb-sparing surgery is usually possible |
| Jaw and skull | Specialist head and neck or neurosurgical teams; reconstruction may be needed |
| Spine | Complex surgery, sometimes combined with radiotherapy |
Complete removal matters. In the German series, seven of eight young patients whose tumours were fully removed at first surgery stayed disease-free, compared with four of seven whose surgery was incomplete (Dantonello et al., 2008).
Chemotherapy
| Regimen | Evidence summary |
|---|---|
| Ewing-type combinations (vincristine, doxorubicin, cyclophosphamide, ifosfamide, etoposide) | Often used before and after surgery in fit patients |
| Other anthracycline regimens | Responses in about a quarter of patients in an Italian series |
| High-dose ifosfamide | No responses in that series |
| Trabectedin | Kept disease stable in a small number of patients with advanced disease |
The Italian Sarcoma Group found that responses to anthracycline treatment were closer to those of soft tissue sarcomas than of Ewing sarcoma. It still suggested that Ewing-type chemotherapy be considered around surgery (Baldi et al., 2026).
Radiotherapy
| Situation | Role |
|---|---|
| Incomplete margins | Reduces the risk of local regrowth |
| Tumours that cannot be removed | Main local treatment |
| Skull base and spine | Proton therapy may be used to protect nearby structures |
| Symptom relief | For painful bone or other metastases |
Treatment of relapse
| Situation | Options |
|---|---|
| Single lung nodules | Surgical removal |
| Local recurrence | Further surgery or radiotherapy |
| Widespread disease | Chemotherapy, trabectedin, clinical trials |
A typical treatment pathway
| Phase | What happens | Typical length |
|---|---|---|
| Diagnosis and staging | Scans, biopsy, molecular testing | 2-4 weeks |
| Chemotherapy before surgery | Several cycles, if recommended | About 3-4 months |
| Surgery | Wide removal and any reconstruction | Hospital stay of days to weeks |
| Treatment after surgery | More chemotherapy and, if needed, radiotherapy | Several months |
| Rehabilitation | Physiotherapy and return to normal activities | Months |
Side effects
| Treatment | Possible side effects |
|---|---|
| Surgery | Pain, wound problems, reduced movement, need for reconstruction |
| Chemotherapy | Hair loss, sickness, infection risk, fertility effects, heart effects with doxorubicin |
| Radiotherapy | Skin changes, tiredness, local scarring, growth effects in young people |
8. Outlook (prognosis)
The outlook varies widely. A key feature of this cancer is its tendency to return late, sometimes more than ten years after treatment. Older reports gave 10-year survival rates below 50% (Dantonello et al., 2008).
| Factor | Effect |
|---|---|
| Localised disease at diagnosis | Better outlook |
| Complete surgical removal | Better outlook |
| Metastases at diagnosis | Poorer outlook |
| Younger age | Some series report better results in young patients |
In the German young-patient series, about two in three were alive at ten years (Dantonello et al., 2008). In the Italian series, patients with localised disease who had Ewing-type chemotherapy had a 5-year survival of 95%, though the numbers were small (Baldi et al., 2026).
Why late relapse matters
Many cancers that stay away for five years are unlikely to come back. Mesenchymal chondrosarcoma is different. Spread to the lungs or bones can appear a decade or more after the first treatment. This is why sarcoma teams keep seeing patients for many years and why any new symptom, even long after treatment, should be reported.
Interestingly, the German series of young patients did not see these late relapses during almost ten years of follow-up. All four recurrences happened within four years (Dantonello et al., 2008). It is not yet clear whether young patients truly behave differently or whether this reflects the small numbers.
9. Follow-up
| Period | Typical checks |
|---|---|
| Years 1-3 | Clinic visit and chest CT every 3-4 months; MRI of the primary site |
| Years 4-5 | Every 6 months |
| Years 5-10 and beyond | Yearly, as late relapse is common |
| Late effects clinic | For young people treated with chemotherapy or radiotherapy |
10. Living with mesenchymal chondrosarcoma
- Attend follow-up for many years, even when you feel well
- Work with physiotherapists to regain strength and movement after surgery
- Discuss fertility preservation before chemotherapy
- Keep up with school, college or work with support from your team
- Ask about late effects, such as heart or hearing checks after chemotherapy
- Seek support from sarcoma charities and teenage and young adult cancer services
For teenagers and young adults
A cancer diagnosis in your teens or twenties can disrupt education, relationships and plans. Many hospitals have teenage and young adult units with youth workers, psychologists and peer support. Ask your team how to access them.
11. Frequently asked questions
| Question | Answer |
|---|---|
| Is it the same as Ewing sarcoma? | No; it can look similar, but it has a different gene fusion and contains cartilage |
| Is it inherited? | No; the gene fusion arises only in the tumour |
| Why is follow-up so long? | The cancer can come back many years later |
| Will I need chemotherapy? | Often, especially for young patients and larger tumours |
| Can I keep my limb? | Most limb tumours can be removed without amputation |
| Can I play sport after treatment? | Often yes, once healing allows; your surgeon and physiotherapist will advise on contact sports |
| Will I need a prosthesis? | Only if the tumour cannot be removed while keeping the limb, which is uncommon |
| Are there targeted drugs? | Not yet approved; research is exploring pathways switched on by the fusion |
12. Questions to ask your care team
- Has the HEY1::NCOA2 fusion been confirmed?
- Has the cancer spread anywhere?
- Can the tumour be removed completely?
- Do you recommend chemotherapy before or after surgery?
- Will I need radiotherapy?
- How will treatment affect my fertility, growth or appearance?
- How long will follow-up last?
- Is there a teenage and young adult service or a clinical trial I could join?
- Who should I contact if I notice a new symptom between visits?
Resources
- Baldi, G.G. et al. (2026) ‘Activity of chemotherapy in mesenchymal chondrosarcoma: a multicentre retrospective analysis within the Italian Sarcoma Group network’, ESMO Open, 11(2), 106080.
- Dantonello, T.M. et al. (2008) ‘Mesenchymal chondrosarcoma of soft tissues and bone in children, adolescents, and young adults: experiences of the CWS and COSS study groups’, Cancer, 112(11), pp. 2424-2431.
- Hameed, M. (2021) ‘Malignant cartilage-forming tumors’, Surgical Pathology Clinics, 14(4), pp. 605-617.
- Qi, W. et al. (2022) ‘Genomic profiling identifies genes and pathways dysregulated by HEY1-NCOA2 fusion and shines a light on mesenchymal chondrosarcoma tumorigenesis’, Journal of Pathology, 257(5), pp. 579-592.
- National Cancer Institute (2026) Childhood Soft Tissue Sarcoma Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/soft-tissue-sarcoma/hp/child-soft-tissue-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.